health
RIO HIV trial links long-acting antibodies to delayed viral rebound
A phase II randomized trial found that two long-acting broadly neutralizing antibodies delayed HIV rebound during closely monitored treatment interruption in men who began antiretroviral therapy early. Secondary analyses linked prolonged control to antibody sensitivity, resistance evolution and a reduction in intact proviral reservoir measurements.